Terms: = Breast cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Treatment
13321 results:
1. Economic evaluation of trastuzumab in her2-positive early breast cancer in Indonesia: A cost-effectiveness analysis.
Khoirunnisa SM; Suryanegara FDA; Setiawan D; Postma MJ; de Jong LA
PLoS One; 2024; 19(5):e0304483. PubMed ID: 38787899
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes.
Chen L; Yan X; Luo T; Tian T; He P; Zhong X
Cancer Med; 2024 May; 13(10):e7295. PubMed ID: 38785215
[TBL] [Abstract] [Full Text] [Related]
3. Systematic literature review of real-world evidence for treatments in HR+/her2- second-line LABC/mBC after first-line treatment with CDK4/6i.
Lambert V; Kane S; Howidi B; Nguyen BN; Chandiwana D; Wu Y; Edwards M; Samjoo IA
BMC Cancer; 2024 May; 24(1):631. PubMed ID: 38783218
[TBL] [Abstract] [Full Text] [Related]
4. Prognosis and influencing factors of ER-positive, her2-low breast cancer patients with residual disease after neoadjuvant chemotherapy: a retrospective study.
Tang L; Jiang L; Shu X; Jin Y; Yu H; Liu S
Sci Rep; 2024 May; 14(1):11761. PubMed ID: 38783028
[TBL] [Abstract] [Full Text] [Related]
5. The Tumor Immune Microenvironment in breast cancer Progression.
Otterlei Fjørtoft M; Huse K; Rye IH
Acta Oncol; 2024 May; 63():359-367. PubMed ID: 38779867
[TBL] [Abstract] [Full Text] [Related]
6. The prognostic marker KRT81 is involved in suppressing CD8 + T cells and predicts immunotherapy response for triple-negative breast cancer.
Yan Z; Zhong Z; Shi C; Feng M; Feng X; Liu T
Cancer Biol Ther; 2024 Dec; 25(1):2355705. PubMed ID: 38778753
[TBL] [Abstract] [Full Text] [Related]
7. Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/her2- metastatic breast cancer: A single center real-world study in China.
Jiang H; Zhong J; Wang J; Song G; Di L; Shao B; Zhang R; Liu Y; Zhu A; Wang N; Li H
Cancer Med; 2024 May; 13(10):e7249. PubMed ID: 38770648
[TBL] [Abstract] [Full Text] [Related]
8. KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges.
Li CY; Wang W; Leung CH; Yang GJ; Chen J
Mol Cancer; 2024 May; 23(1):109. PubMed ID: 38769556
[TBL] [Abstract] [Full Text] [Related]
9. Retrospective analysis of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (her2), Ki67 changes and their clinical significance between primary breast cancer and metastatic tumors.
Qi G; Zhang X; Gai X; Yan X
PeerJ; 2024; 12():e17377. PubMed ID: 38766488
[TBL] [Abstract] [Full Text] [Related]
10. The impact of loco-regional treatment modality on the outcomes in breast cancer patients younger than forty years of age.
Boutrus RR; Abdelazim YA; Mohammed T; Bayomy M; Ibraheem MH; Hussein A; Sebaie ME
BMC Cancer; 2024 May; 24(1):599. PubMed ID: 38760780
[TBL] [Abstract] [Full Text] [Related]
11. Visceral crisis in metastatic breast cancer: an old concept with new perspectives.
Andrade MO; Bonadio RRDCC; Diz MDPE; Testa L
Clinics (Sao Paulo); 2024; 79():100362. PubMed ID: 38754225
[TBL] [Abstract] [Full Text] [Related]
12. Clinicopathologic features and genomic profiling of female axillary lymph node metastases from adenocarcinoma or poorly differentiated carcinoma of unknown primary.
Tang L; Zhu Y; Du Y; Long X; Long Y; Tang Y; Liu J
J Cancer Res Clin Oncol; 2024 May; 150(5):256. PubMed ID: 38750402
[TBL] [Abstract] [Full Text] [Related]
13. Neoadjuvant radiotherapy in ER
Bruss C; Albert V; Seitz S; Blaimer S; Kellner K; Pohl F; Ortmann O; Brockhoff G; Wege AK
Front Immunol; 2024; 15():1355130. PubMed ID: 38742103
[TBL] [Abstract] [Full Text] [Related]
14. Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery.
Sturniolo I; Váróczy C; Bede ÁM; Hegedűs C; Demény MÁ; Virág L
J Vis Exp; 2024 Apr; (206):. PubMed ID: 38738886
[TBL] [Abstract] [Full Text] [Related]
15. Efficacy and safety of pyrotinib combined with albumin-bound paclitaxel as first-line treatment for her2-positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single-arm, phase 2 prospective clinical trial.
Man X; Huang J; Sun S; Zhou D; Zhang B; Fang S; Zheng F; Li C; Wang X; Huang W; Wang L; He Q; Fu H; Zhang Y; Liu C; Dong L; Zhao X; Xu L; Sun X; Fan B; Song L; Zhou Z; Yu J; Li H
Clin Transl Med; 2024 May; 14(5):e1687. PubMed ID: 38738791
[TBL] [Abstract] [Full Text] [Related]
16. Metaplastic breast cancer with a unique presentation and complete response to chemotherapy: a case report.
Nahhat F; Doyya M; Zabad K; Ksiri H
BMC Womens Health; 2024 May; 24(1):285. PubMed ID: 38734591
[TBL] [Abstract] [Full Text] [Related]
17. Trastuzumab deruxtecan in previously treated her2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
Petit T; Hajjaji N; Antoine EC; Benderra MA; Gozy M; Foa C; Mouysset JL; Grenier J; Mousseau M; Mailliez A; Saghatchian M; Lachaier E; Desmoulins I; Hennequin A; Maes P; Loirat D; Ricci F; Diéras V; Berton D; Tiong FL; Teixeira L; Dohollou N; Lévy C; Bachelot T; Pierga JY
Cancer Med; 2024 May; 13(9):e7168. PubMed ID: 38733172
[TBL] [Abstract] [Full Text] [Related]
18. Comparison of anthracycline-containing and anthracycline-free regimens in neoadjuvant her-2 positive breast cancer treatment.
Bardakci M; Karakas H; Bayram D; Avci N; Kitapli S; Ozen M; Aslan F; Koseoglu C; Kadioglu A; Onur ID; Sakalar T; Buyuksimsek M; Alkan A; Ergun Y; Kaya AO; Bilgin B; Yalcin B
Sci Rep; 2024 May; 14(1):10632. PubMed ID: 38724585
[TBL] [Abstract] [Full Text] [Related]
19. Deep learning-assisted monitoring of trastuzumab efficacy in her2-Overexpressing breast cancer via SERS immunoassays of tumor-derived urinary exosomal biomarkers.
Kim J; Son HY; Lee S; Rho HW; Kim R; Jeong H; Park C; Mun B; Moon Y; Jeong E; Lim EK; Haam S
Biosens Bioelectron; 2024 Aug; 258():116347. PubMed ID: 38723332
[TBL] [Abstract] [Full Text] [Related]
20. Incidence and survival of primary metastatic breast cancer in Denmark; implication of breast cancer screening, classification, and staging practice.
Berg T; Jensen MB; Rossing M; Axelsen CT; Kümler I; Søndergaard L; Vogsen M; Knoop AS; Ejlertsen B
Acta Oncol; 2024 May; 63():277-287. PubMed ID: 38711384
[TBL] [Abstract] [Full Text] [Related]
[Next]
